Royalty Pharma RPRX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on trailing twelve months.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's EBITDA margin?
- Royalty Pharma (RPRX) reported EBITDA margin of 57.1% in Q4 2024.
- How has Royalty Pharma's EBITDA margin changed year-over-year?
- Royalty Pharma's EBITDA margin decreased by 9.9% year-over-year, from 63.4% to 57.1%.
- What is the long-term trend for Royalty Pharma's EBITDA margin?
- Over 3 years (2020 to 2024), Royalty Pharma's EBITDA margin has grown at a -9.2% compound annual growth rate (CAGR), from 76.3% to 57.1%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.